Rasburicase and Tumor Lysis Syndrome: Lower Dosage, Consideration of Indications, and Hyperhydration

被引：17
|
作者：
Darmon, Michael [1 ]
Guichard, Isabelle [1 ]
Vincent, Francois [2 ]
机构：
[1] St Etienne Teaching Hosp, St Etienne, France
[2] Avicenne Teaching Hosp, Bobigny, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 03期
关键词：
SINGLE-DOSE RASBURICASE; 6; MG; ADULTS; HYPERURICEMIA; PROPHYLAXIS; MANAGEMENT; CANCER;
D O I：
10.1200/JCO.2010.32.6751
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E67 / E68
页数：2
相关论文
共 50 条
  • [1] Rasburicase in Tumor Lysis Syndrome of the Adult: A Systematic Review and Meta-analysis
    Lopez-Olivo, Maria A.
    Pratt, Gregory
    Palla, Shana L.
    Salahudeen, Abdulla
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2013, 62 (03) : 481 - 492
  • [2] Rasburicase in treating tumor lysis syndrome: An umbrella review
    Mahfooz, Kamran
    Sohail, Haris
    Gvajaia, Ani
    Arif, Uroosa
    Grewal, Daisy
    Muppidi, Monica Reddy
    Vohra, Vanya
    Tarique, Aamir
    Vasavada, Advait
    CANCER PATHOGENESIS AND THERAPY, 2023, 1 (04): : 262 - 271
  • [3] Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience
    Takai, Mihoko
    Yamauchi, Takahiro
    Matsuda, Yasufumi
    Tai, Katsunori
    Ikegaya, Satoshi
    Kishi, Shinji
    Urasaki, Yoshimasa
    Yoshida, Akira
    Iwasaki, Hiromichi
    Ueda, Takanori
    ONCOLOGY LETTERS, 2015, 9 (05) : 2119 - 2125
  • [4] Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma
    Personett, Heather A.
    Barreto, Erin F.
    McCullough, Kristen B.
    Dierkhising, Ross
    Leung, Nelson
    Habermann, Thomas M.
    LEUKEMIA & LYMPHOMA, 2019, 60 (09) : 2271 - 2277
  • [5] Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies
    Yaman, Samet
    Basci, Semih
    Turan, Gokhan
    Ulu, Bahar Uncu
    Yigenoglu, Tugce Nur
    Dal, Mehmet Sinan
    Cakar, Merih Kizil
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (02) : E71 - E76
  • [6] Clarifying the role of rasburicase in tumor lysis syndrome
    Sood, Amy R.
    Burry, Lisa D.
    Cheng, Doret K. E.
    PHARMACOTHERAPY, 2007, 27 (01): : 111 - 121
  • [7] Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase
    Alakel, Nael
    Middeke, Jan Moritz
    Schetelig, Johannes
    Bornhaeuser, Martin
    ONCOTARGETS AND THERAPY, 2017, 10 : 597 - 605
  • [8] Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome
    Jeon, Young-Woo
    Kwak, Dae-Hun
    Park, Sung-Soo
    Yoon, Jae-Ho
    Lee, Sung-Eun
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Kim, Hee-Je
    Lee, Seok
    Min, Chang-Ki
    Lee, Jong-Wook
    Min, Woo-Sung
    Cho, Seok-Goo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (09) : 595 - 603
  • [9] Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients
    Gupta, Gopila
    Seth, Tulika
    Garg, Vikas
    Juneja, Richa
    Mahapatra, Manoranjan
    Datta, Sudip Kumar
    Upadhyay, Ashish Datt
    Saxena, Renu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (01) : E99 - E104
  • [10] Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome
    Sanchez Tatay, V.
    Lopez Castilla, J. D.
    Carmona Ponce, J. M.
    Perez Hurtado, J. M.
    Quiroga Cantero, E.
    Loscertales Abril, M.
    ANALES DE PEDIATRIA, 2010, 72 (02): : 103 - 110
12345